Department of Critical Care Medicine, Center of Severe Acute Pancreatitis (CSAP), School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China.
National Institute of Healthcare Data Science at Nanjing University, Nanjing, China.
J Hepatobiliary Pancreat Sci. 2021 Apr;28(4):387-396. doi: 10.1002/jhbp.915. Epub 2021 Mar 18.
BACKGROUND/PURPOSE: The current standard care for acute pancreatitis with acute necrotic collections (ANC) is to postpone invasive intervention for 4 weeks when indicated. However, in patients with persistent organ failure (POF), this delayed approach may prolong organ failure. In this study, we aimed to assess the feasibility and safety of earlier drainage for acute pancreatitis patients with ANC and POF.
A single-center, randomized controlled trial was conducted. Eligible patients were randomly assigned to either the early on-demand (EOD) group or the standard management (SM) group. Within 21 days of randomization, early drainage was triggered by unremitted or worsening organ failure in the EOD group. The primary endpoint was a composite of major complications/death during 90-days follow-up.
Thirty patients were randomized. Within 21 days of randomization, eight of the 15 patients (53%) in the EOD group underwent percutaneous drainage compared to four of the 15 patients (27%) in the SM group (P = 0.26). The primary outcome occurred in three of the 15 (20%) patients in the EOD group and seven of the 15(46.7%) in the controls (P = 0.25, relative risk 0.43, 95%CI 0.14 to 1.35).
Although the EOD approach did not result in significant differences between groups, the primary outcome assessed in this trial demonstrated the potential for clinical benefits favoring early drainage.
背景/目的:对于伴有急性坏死性积聚(ANC)的急性胰腺炎,目前的标准治疗是在有指征时延迟 4 周进行侵入性干预。然而,对于持续性器官衰竭(POF)的患者,这种延迟方法可能会延长器官衰竭时间。在本研究中,我们旨在评估 ANC 和 POF 急性胰腺炎患者早期引流的可行性和安全性。
进行了一项单中心、随机对照试验。符合条件的患者被随机分配到早期按需(EOD)组或标准治疗(SM)组。在随机分组后 21 天内,EOD 组通过持续或恶化的器官衰竭触发早期引流。主要终点是 90 天随访期间的主要并发症/死亡的复合终点。
30 名患者被随机分组。在随机分组后 21 天内,EOD 组的 15 名患者中有 8 名(53%)接受了经皮引流,而 SM 组的 15 名患者中有 4 名(27%)(P=0.26)。EOD 组的 15 名患者中有 3 名(20%)和对照组的 15 名患者中有 7 名(46.7%)发生了主要结局(P=0.25,相对风险 0.43,95%CI 0.14 至 1.35)。
尽管 EOD 方法并未导致两组之间产生显著差异,但本试验评估的主要结局表明早期引流具有潜在的临床获益。